{"success":true,"data":{"pressRelease":{"id":"129804","rtpr_id":"nGNX67wSMX","ticker":"OTLK","exchange":"NASDAQ","all_tickers":["OTLK"],"title":"Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™","author":"Globe Newswire","published_at":"2026-08-27T20:05:00.352Z","article_body":"Seasoned finance executive brings more than 20 years of leadership experience\nacross global commercial organizations, including the pharmaceutical and\nmedical technology industries\n\nDeep expertise spans commercial operations, capital markets, public company\nfinance, and building scalable financial and operational infrastructure\n\nAppointment strengthens financial and operational infrastructure as Company\nprepares for U.S. commercial launch following FDA approval of LYTENAVA™\n\nISELIN, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=CyZT4aIDUSSwnspj52nk9COHhwXwyoQ_ia7D3h_Vkh0PQNKLV24P_oUUh0faG8CC_0FpPU-TljMg2xRuf9GEXqzWWfPWnZ2oAGAExjX1SPU=)\n(Nasdaq: OTLK), a biopharmaceutical company focused on the development and\ncommercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the\ntreatment of retinal diseases, today announced the appointment of Kevin\nLundquist as Chief Financial Officer, effective September 1, 2026. Mr.\nLundquist joins Outlook Therapeutics at a defining point in the Company’s\nevolution, following U.S. Food and Drug Administration (“FDA”) approval of\nLYTENAVA, as the Company builds the financial and operational infrastructure\nto support its planned U.S. commercial launch.\n\n“FDA approval of LYTENAVA fundamentally changes the opportunity in front of\nOutlook Therapeutics, and Kevin is exactly the caliber of executive we need as\nwe enter this next phase,” said Bob Jahr, Chief Executive Officer of Outlook\nTherapeutics. “He brings an exceptional combination of financial and\noperational leadership, capital markets expertise, and experience leading\nfinance functions across large-scale pharmaceutical and commercial\norganizations. Importantly, Kevin has firsthand experience building the\nfinancial and operational infrastructure needed to support approved commercial\nproducts. As we turn our focus toward executing on the opportunity created by\nLYTENAVA’s approval, Kevin will be instrumental in helping us build a\ndisciplined, scalable organization positioned to drive long-term growth and\nshareholder value.”\n\nMr. Lundquist brings more than 20 years of corporate finance and capital\nmarkets experience across the pharmaceutical, biotechnology, medical\ntechnology, and manufacturing industries. He has extensive experience leading\nfinance organizations for both public and private equity-backed companies,\nincluding commercial-stage businesses, and has direct experience supporting\nIPOs, commercial operations, SEC reporting, investor relations, capital\nraising, M&A, treasury, and financial infrastructure.\n\nMr. Lundquist most recently served as Chief Financial Officer of CapsoVision,\nInc., a commercial-stage medical technology Company, where he oversaw finance\nand operations, investor relations, SEC reporting, audit, financial planning,\ninvestment banking relationships, and capital raises. He led the company\nthrough its 2025 IPO process, and helped build its finance and accounting\ninfrastructure, including key hires and ERP implementation. He also supported\nthe development of the Company’s commercial organization and managed the P&L\nfor approved commercial products.\n\nPreviously, Mr. Lundquist served as Chief Financial Officer of Abzena\nBiologics, a private equity-backed contract development and manufacturing\norganization, where he was responsible for the Company’s financial and\nstrategic direction, including IPO preparation, long-term strategy, supply\nchain, investor relations, banking, and board reporting. He also previously\nserved as Vice President of Finance at Revance Therapeutics, where he oversaw\nfinancial operations, SEC reporting, treasury, capital raises, M&A, and\ncommercial and operating strategies.\n\nEarlier in his career, Mr. Lundquist served as Global Head of Finance for\nGenentech/Roche’s Drug Substance Biologics Operations, where he supported a\nglobal biologics manufacturing network encompassing six manufacturing sites\nand multiple contract manufacturers. He also served as Chief Financial Officer\nof Caterpillar’s Japan division, overseeing a $6 billion annual-revenue\nbusiness, and held a variety of finance and corporate audit positions at\nAbbott Laboratories. He holds an M.B.A. in Finance from Utah State University\nand a Bachelor of Science in Accounting and Finance from the University of\nUtah.\n\n“This is an extraordinary time to join Outlook Therapeutics,” said Mr.\nLundquist. “LYTENAVA has the potential to address an important need in\nretinal care, and FDA approval provides the foundation from which to build its\nU.S. market presence. I am excited to work alongside Bob and the entire\nOutlook team to help translate that opportunity into meaningful commercial\ngrowth. My priorities will include maintaining financial discipline,\nallocating capital toward the Company’s highest-value opportunities, and\nensuring Outlook has the resources and capabilities needed to execute its U.S.\nlaunch strategy.”\n\nIn connection with Mr. Lundquist’s appointment, Lawrence Kenyon will step\ndown as Chief Financial Officer effective September 1, 2026. Mr. Kenyon will\ncontinue to support the Company as a non-executive employee through September\n30, 2026.\n\n“On behalf of Outlook Therapeutics, I want to thank Larry for his many years\nof leadership and service,” added Mr. Jahr. “His unwavering dedication and\nvaluable contributions helped guide the Company through years of clinical and\nregulatory advancements culminating in the FDA approval of LYTENAVA. We are\ntruly grateful for his partnership and wish him every success in the\nfuture.”\n\nInducement Grant\n\nAdditionally, Outlook Therapeutics announced that the Compensation Committee\nof its Board of Directors approved the issuance of an option to purchase\n500,000 shares of common stock to Mr. Lundquist in accordance with Nasdaq\nListing Rule 5635(c)(4), as a material inducement to Mr. Lundquist’s start\nof employment with Outlook Therapeutics.\n\nThe option will be issued on September 1, 2026, with an exercise price per\nshare equivalent to the closing price of Outlook Therapeutics’ common stock\non the date of grant. The option will vest over four years, with 25% of the\nshares subject to the option vesting on the first anniversary of the grant\ndate, with the remaining shares vesting in equal monthly installments over the\nthree years thereafter, subject to Mr. Lundquist’s continuous service\nthrough the applicable vesting date.\n\nAbout LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)\n\nLYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the\nUnited States for the treatment of wet AMD. In the United States, LYTENAVA\n(bevacizumab-vikg) is the only ophthalmic formulation approved by the FDA.\nLYTENAVA (bevacizumab gamma) is also the subject of a centralized Marketing\nAuthorization granted by the European Commission in the EU and Marketing\nAuthorization granted by the Medicines and Healthcare products Regulatory\nAgency (MHRA) in the UK for the treatment of wet AMD. In certain European\nUnion Member States, LYTENAVA must receive pricing and reimbursement approval\nbefore it can be sold.\n\nBevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant\nhumanized IgG1 monoclonal antibody specific to human vascular endothelial\ngrowth factor (VEGF). Bevacizumab binds VEGF and prevents the interaction of\nVEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells.\nLYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with\nreceptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses\nendothelial cell proliferation, neovascularization, and vascular permeability.\nInhibition of such activity targets a pathophysiologic process that\ncontributes to vision loss.\n\nImportant Safety Information and Indication\n\nLYTENAVA (bevacizumab-vikg) is a vascular endothelial growth factor (VEGF)\ninhibitor indicated for the treatment of patients with neovascular (wet)\nage-related macular degeneration (nAMD).\n\nContraindications\n\nLYTENAVA is contraindicated in patients with ocular or periocular infections,\nin patients with active intraocular inflammation, and in patients with a known\nhypersensitivity to bevacizumab products or any of the ingredients in\nLYTENAVA. Hypersensitivity reactions may manifest as severe intraocular\ninflammation.\n\nWarnings and Precautions\n\nIntravitreal injections have been associated with endophthalmitis and retinal\ndetachments. Proper aseptic injection technique must always be used when\nadministering LYTENAVA. In addition, patients should be monitored following\nthe injection to permit early treatment should an infection occur.\n\nIncreases in intraocular pressure have been noted post-injection (up to 60\nminutes) while being treated with LYTENAVA. Monitor intraocular pressure prior\nto and following intravitreal injection with LYTENAVA and manage\nappropriately.\n\nAlthough there was a low rate of arterial thromboembolic events (ATEs)\nobserved in the LYTENAVA clinical trials, there is a potential risk of ATEs\nfollowing intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal\nstroke, nonfatal myocardial infarction, or vascular death (including deaths of\nunknown cause).\n\nAdverse Reactions\n\nThe most common adverse reaction (≥1%) reported in patients receiving\nLYTENAVA was conjunctival hemorrhage (4%), eye pain (2%), and vitreous\nfloaters (2%). These are not all the possible side effects of LYTENAVA.\n\nYou are encouraged to report side effects of prescription drugs to the FDA.\n\nVisit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side\neffects to Outlook Therapeutics at 1-833-999-OTLK (6855).\n\nPlease see the full U.S. Prescribing Information for LYTENAVA here.\n\nAbout Outlook Therapeutics, Inc.\n\nOutlook Therapeutics is a biopharmaceutical company focused on the development\nand commercialization of LYTENAVA (bevacizumab-vikg (U.S.), bevacizumab gamma\n(E.U.)). LYTENAVA is the only ophthalmic formulation of bevacizumab to receive\nU.S. FDA approval and European Commission and MHRA Marketing Authorization for\nthe treatment of wet AMD. Outlook Therapeutics commenced commercial launch of\nLYTENAVA (bevacizumab gamma) in Germany, Austria, and the UK as a treatment\nfor wet AMD.\n\nForward-Looking Statements\n\nThis press release contains statements that may or are considered\n“forward-looking statements”. All statements other than statements of\nhistorical facts are “forward-looking statements,” including those\nrelating to future events. In some cases, you can identify forward-looking\nstatements by terminology such as “anticipate,” “believe,” “can,”\n“could,” “continue,” “expect,” “may,” “on track,”\n“plan,” “potential,” “target,” “will,” or “would”, the\nnegative of terms like these or other comparable terminology, and other words\nor terms of similar meaning. These include, among others, express or implied\ndiscussions regarding the Company’s planned launch of LYTENAVA in the United\nStates and other jurisdictions and the timing thereof; expectations concerning\npotential revenue generation from sales of LYTENAVA; expectations surrounding\nmarket adoption of LYTENAVA; expectations regarding the potential impact of\nLYTENAVA in the retina community; Outlook Therapeutics’ development or\nfuture revenue plans for LYTENAVA generally; and other statements that are not\nhistorical fact. Although Outlook Therapeutics believes that it has a\nreasonable basis for the forward-looking statements contained herein, they are\nbased on current expectations about future events affecting Outlook\nTherapeutics and are subject to risks, uncertainties, and factors relating to\nits operations and business environment, all of which are difficult to predict\nand many of which are beyond its control. These risk factors include those\nrisks associated with developing and commercializing pharmaceutical product\ncandidates, risks in obtaining necessary regulatory approvals, the content and\ntiming of decisions by regulatory bodies, as well as those risks detailed in\nOutlook Therapeutics’ filings with the Securities and Exchange Commission\n(the SEC), including the Current Report on Form 8-K filed with the SEC on\nAugust 12, 2026 and the Quarterly Report on Form 10-Q for the quarter ended\nJune 30, 2026, and future reports Outlook Therapeutics files with the SEC,\nwhich include uncertainty of market conditions and future impacts related to\nmacroeconomic factors, including as a result of the ongoing overseas\nconflicts, tariffs, and trade tensions, fluctuations in interest rates and\ninflation, and potential future bank failures on the global business\nenvironment. These risks may cause actual results to differ materially from\nthose expressed or implied by forward-looking statements in this press\nrelease. All forward-looking statements included in this press release are\nexpressly qualified in their entirety by the foregoing cautionary statements.\nYou are cautioned not to place undue reliance on these forward-looking\nstatements, which speak only as of the date hereof. Outlook Therapeutics does\nnot undertake any obligation to update, amend, or clarify these\nforward-looking statements, whether as a result of new information, future\nevents, or otherwise, except as may be required under applicable securities\nlaw.\n\nInvestor Inquiries:\nJenene Thomas\nChief Executive Officer\nJTC Team, LLC\nT: 908.824.0775\n\nA photo accompanying this announcement is available at\nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/d9ae289f-ed49-4a8a-a8f6-edb7c5fa1cca\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cbff3302-f8d2-466a-beff-8c33252f9c70)\nKevin Lundquist \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d9ae289f-ed49-4a8a-a8f6-edb7c5fa1cca/en)\nKevin Lundquist\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX67wSMX","title":"Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™","author":"Globe Newswire","ticker":"OTLK","created":"2026-08-27T20:05:00.352Z","tickers":["OTLK"],"exchange":"NASDAQ","article_body":"Seasoned finance executive brings more than 20 years of leadership experience\nacross global commercial organizations, including the pharmaceutical and\nmedical technology industries\n\nDeep expertise spans commercial operations, capital markets, public company\nfinance, and building scalable financial and operational infrastructure\n\nAppointment strengthens financial and operational infrastructure as Company\nprepares for U.S. commercial launch following FDA approval of LYTENAVA™\n\nISELIN, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=CyZT4aIDUSSwnspj52nk9COHhwXwyoQ_ia7D3h_Vkh0PQNKLV24P_oUUh0faG8CC_0FpPU-TljMg2xRuf9GEXqzWWfPWnZ2oAGAExjX1SPU=)\n(Nasdaq: OTLK), a biopharmaceutical company focused on the development and\ncommercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the\ntreatment of retinal diseases, today announced the appointment of Kevin\nLundquist as Chief Financial Officer, effective September 1, 2026. Mr.\nLundquist joins Outlook Therapeutics at a defining point in the Company’s\nevolution, following U.S. Food and Drug Administration (“FDA”) approval of\nLYTENAVA, as the Company builds the financial and operational infrastructure\nto support its planned U.S. commercial launch.\n\n“FDA approval of LYTENAVA fundamentally changes the opportunity in front of\nOutlook Therapeutics, and Kevin is exactly the caliber of executive we need as\nwe enter this next phase,” said Bob Jahr, Chief Executive Officer of Outlook\nTherapeutics. “He brings an exceptional combination of financial and\noperational leadership, capital markets expertise, and experience leading\nfinance functions across large-scale pharmaceutical and commercial\norganizations. Importantly, Kevin has firsthand experience building the\nfinancial and operational infrastructure needed to support approved commercial\nproducts. As we turn our focus toward executing on the opportunity created by\nLYTENAVA’s approval, Kevin will be instrumental in helping us build a\ndisciplined, scalable organization positioned to drive long-term growth and\nshareholder value.”\n\nMr. Lundquist brings more than 20 years of corporate finance and capital\nmarkets experience across the pharmaceutical, biotechnology, medical\ntechnology, and manufacturing industries. He has extensive experience leading\nfinance organizations for both public and private equity-backed companies,\nincluding commercial-stage businesses, and has direct experience supporting\nIPOs, commercial operations, SEC reporting, investor relations, capital\nraising, M&A, treasury, and financial infrastructure.\n\nMr. Lundquist most recently served as Chief Financial Officer of CapsoVision,\nInc., a commercial-stage medical technology Company, where he oversaw finance\nand operations, investor relations, SEC reporting, audit, financial planning,\ninvestment banking relationships, and capital raises. He led the company\nthrough its 2025 IPO process, and helped build its finance and accounting\ninfrastructure, including key hires and ERP implementation. He also supported\nthe development of the Company’s commercial organization and managed the P&L\nfor approved commercial products.\n\nPreviously, Mr. Lundquist served as Chief Financial Officer of Abzena\nBiologics, a private equity-backed contract development and manufacturing\norganization, where he was responsible for the Company’s financial and\nstrategic direction, including IPO preparation, long-term strategy, supply\nchain, investor relations, banking, and board reporting. He also previously\nserved as Vice President of Finance at Revance Therapeutics, where he oversaw\nfinancial operations, SEC reporting, treasury, capital raises, M&A, and\ncommercial and operating strategies.\n\nEarlier in his career, Mr. Lundquist served as Global Head of Finance for\nGenentech/Roche’s Drug Substance Biologics Operations, where he supported a\nglobal biologics manufacturing network encompassing six manufacturing sites\nand multiple contract manufacturers. He also served as Chief Financial Officer\nof Caterpillar’s Japan division, overseeing a $6 billion annual-revenue\nbusiness, and held a variety of finance and corporate audit positions at\nAbbott Laboratories. He holds an M.B.A. in Finance from Utah State University\nand a Bachelor of Science in Accounting and Finance from the University of\nUtah.\n\n“This is an extraordinary time to join Outlook Therapeutics,” said Mr.\nLundquist. “LYTENAVA has the potential to address an important need in\nretinal care, and FDA approval provides the foundation from which to build its\nU.S. market presence. I am excited to work alongside Bob and the entire\nOutlook team to help translate that opportunity into meaningful commercial\ngrowth. My priorities will include maintaining financial discipline,\nallocating capital toward the Company’s highest-value opportunities, and\nensuring Outlook has the resources and capabilities needed to execute its U.S.\nlaunch strategy.”\n\nIn connection with Mr. Lundquist’s appointment, Lawrence Kenyon will step\ndown as Chief Financial Officer effective September 1, 2026. Mr. Kenyon will\ncontinue to support the Company as a non-executive employee through September\n30, 2026.\n\n“On behalf of Outlook Therapeutics, I want to thank Larry for his many years\nof leadership and service,” added Mr. Jahr. “His unwavering dedication and\nvaluable contributions helped guide the Company through years of clinical and\nregulatory advancements culminating in the FDA approval of LYTENAVA. We are\ntruly grateful for his partnership and wish him every success in the\nfuture.”\n\nInducement Grant\n\nAdditionally, Outlook Therapeutics announced that the Compensation Committee\nof its Board of Directors approved the issuance of an option to purchase\n500,000 shares of common stock to Mr. Lundquist in accordance with Nasdaq\nListing Rule 5635(c)(4), as a material inducement to Mr. Lundquist’s start\nof employment with Outlook Therapeutics.\n\nThe option will be issued on September 1, 2026, with an exercise price per\nshare equivalent to the closing price of Outlook Therapeutics’ common stock\non the date of grant. The option will vest over four years, with 25% of the\nshares subject to the option vesting on the first anniversary of the grant\ndate, with the remaining shares vesting in equal monthly installments over the\nthree years thereafter, subject to Mr. Lundquist’s continuous service\nthrough the applicable vesting date.\n\nAbout LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)\n\nLYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the\nUnited States for the treatment of wet AMD. In the United States, LYTENAVA\n(bevacizumab-vikg) is the only ophthalmic formulation approved by the FDA.\nLYTENAVA (bevacizumab gamma) is also the subject of a centralized Marketing\nAuthorization granted by the European Commission in the EU and Marketing\nAuthorization granted by the Medicines and Healthcare products Regulatory\nAgency (MHRA) in the UK for the treatment of wet AMD. In certain European\nUnion Member States, LYTENAVA must receive pricing and reimbursement approval\nbefore it can be sold.\n\nBevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant\nhumanized IgG1 monoclonal antibody specific to human vascular endothelial\ngrowth factor (VEGF). Bevacizumab binds VEGF and prevents the interaction of\nVEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells.\nLYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with\nreceptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses\nendothelial cell proliferation, neovascularization, and vascular permeability.\nInhibition of such activity targets a pathophysiologic process that\ncontributes to vision loss.\n\nImportant Safety Information and Indication\n\nLYTENAVA (bevacizumab-vikg) is a vascular endothelial growth factor (VEGF)\ninhibitor indicated for the treatment of patients with neovascular (wet)\nage-related macular degeneration (nAMD).\n\nContraindications\n\nLYTENAVA is contraindicated in patients with ocular or periocular infections,\nin patients with active intraocular inflammation, and in patients with a known\nhypersensitivity to bevacizumab products or any of the ingredients in\nLYTENAVA. Hypersensitivity reactions may manifest as severe intraocular\ninflammation.\n\nWarnings and Precautions\n\nIntravitreal injections have been associated with endophthalmitis and retinal\ndetachments. Proper aseptic injection technique must always be used when\nadministering LYTENAVA. In addition, patients should be monitored following\nthe injection to permit early treatment should an infection occur.\n\nIncreases in intraocular pressure have been noted post-injection (up to 60\nminutes) while being treated with LYTENAVA. Monitor intraocular pressure prior\nto and following intravitreal injection with LYTENAVA and manage\nappropriately.\n\nAlthough there was a low rate of arterial thromboembolic events (ATEs)\nobserved in the LYTENAVA clinical trials, there is a potential risk of ATEs\nfollowing intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal\nstroke, nonfatal myocardial infarction, or vascular death (including deaths of\nunknown cause).\n\nAdverse Reactions\n\nThe most common adverse reaction (≥1%) reported in patients receiving\nLYTENAVA was conjunctival hemorrhage (4%), eye pain (2%), and vitreous\nfloaters (2%). These are not all the possible side effects of LYTENAVA.\n\nYou are encouraged to report side effects of prescription drugs to the FDA.\n\nVisit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side\neffects to Outlook Therapeutics at 1-833-999-OTLK (6855).\n\nPlease see the full U.S. Prescribing Information for LYTENAVA here.\n\nAbout Outlook Therapeutics, Inc.\n\nOutlook Therapeutics is a biopharmaceutical company focused on the development\nand commercialization of LYTENAVA (bevacizumab-vikg (U.S.), bevacizumab gamma\n(E.U.)). LYTENAVA is the only ophthalmic formulation of bevacizumab to receive\nU.S. FDA approval and European Commission and MHRA Marketing Authorization for\nthe treatment of wet AMD. Outlook Therapeutics commenced commercial launch of\nLYTENAVA (bevacizumab gamma) in Germany, Austria, and the UK as a treatment\nfor wet AMD.\n\nForward-Looking Statements\n\nThis press release contains statements that may or are considered\n“forward-looking statements”. All statements other than statements of\nhistorical facts are “forward-looking statements,” including those\nrelating to future events. In some cases, you can identify forward-looking\nstatements by terminology such as “anticipate,” “believe,” “can,”\n“could,” “continue,” “expect,” “may,” “on track,”\n“plan,” “potential,” “target,” “will,” or “would”, the\nnegative of terms like these or other comparable terminology, and other words\nor terms of similar meaning. These include, among others, express or implied\ndiscussions regarding the Company’s planned launch of LYTENAVA in the United\nStates and other jurisdictions and the timing thereof; expectations concerning\npotential revenue generation from sales of LYTENAVA; expectations surrounding\nmarket adoption of LYTENAVA; expectations regarding the potential impact of\nLYTENAVA in the retina community; Outlook Therapeutics’ development or\nfuture revenue plans for LYTENAVA generally; and other statements that are not\nhistorical fact. Although Outlook Therapeutics believes that it has a\nreasonable basis for the forward-looking statements contained herein, they are\nbased on current expectations about future events affecting Outlook\nTherapeutics and are subject to risks, uncertainties, and factors relating to\nits operations and business environment, all of which are difficult to predict\nand many of which are beyond its control. These risk factors include those\nrisks associated with developing and commercializing pharmaceutical product\ncandidates, risks in obtaining necessary regulatory approvals, the content and\ntiming of decisions by regulatory bodies, as well as those risks detailed in\nOutlook Therapeutics’ filings with the Securities and Exchange Commission\n(the SEC), including the Current Report on Form 8-K filed with the SEC on\nAugust 12, 2026 and the Quarterly Report on Form 10-Q for the quarter ended\nJune 30, 2026, and future reports Outlook Therapeutics files with the SEC,\nwhich include uncertainty of market conditions and future impacts related to\nmacroeconomic factors, including as a result of the ongoing overseas\nconflicts, tariffs, and trade tensions, fluctuations in interest rates and\ninflation, and potential future bank failures on the global business\nenvironment. These risks may cause actual results to differ materially from\nthose expressed or implied by forward-looking statements in this press\nrelease. All forward-looking statements included in this press release are\nexpressly qualified in their entirety by the foregoing cautionary statements.\nYou are cautioned not to place undue reliance on these forward-looking\nstatements, which speak only as of the date hereof. Outlook Therapeutics does\nnot undertake any obligation to update, amend, or clarify these\nforward-looking statements, whether as a result of new information, future\nevents, or otherwise, except as may be required under applicable securities\nlaw.\n\nInvestor Inquiries:\nJenene Thomas\nChief Executive Officer\nJTC Team, LLC\nT: 908.824.0775\n\nA photo accompanying this announcement is available at\nhttps://www.globenewswire.com/NewsRoom/AttachmentNg/d9ae289f-ed49-4a8a-a8f6-edb7c5fa1cca\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cbff3302-f8d2-466a-beff-8c33252f9c70)\nKevin Lundquist \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d9ae289f-ed49-4a8a-a8f6-edb7c5fa1cca/en)\nKevin Lundquist\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-27T20:05:00.478512858Z","server_sent_at_ms":1787861100478},"received_at":"2026-08-27T20:05:01.451Z","source_url":"https://www.globenewswire.com/news-release/2026/08/27/3352397/0/en/outlook-therapeutics-appoints-kevin-lundquist-as-chief-financial-officer-as-it-prepares-for-u-s-commercial-launch-of-lytenava.html"},"analysis":{"id":"118724","press_release_id":"129804","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"Outlook Therapeutics appointed Kevin Lundquist as Chief Financial Officer, effective September 1, 2026, bringing over 20 years of experience in pharmaceutical and medical technology finance to the role as the company prepares for the U.S. commercial launch of LYTENAVA.\n\nOutgoing CFO Lawrence Kenyon will step down on September 1 but will remain as a non-executive employee through the end of the month to ensure a smooth transition.\n\nThe company issued an inducement grant to Mr. Lundquist for an option to purchase 500,000 shares of common stock, vesting over four years.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"CFO hire signals preparation for commercial ramp."},"keyFigures":{"customDimensions":{"inducement_grant_shares":500000}},"quotedText":"This is an extraordinary time to join Outlook Therapeutics","namedEntities":{"people":[{"name":"Kevin Lundquist","role":"Chief Financial Officer"},{"name":"Bob Jahr","role":"Chief Executive Officer"},{"name":"Lawrence Kenyon","role":"Outgoing Chief Financial Officer"}],"products":["LYTENAVA™"],"companies":[{"name":"Outlook Therapeutics, Inc.","ticker":"OTLK"},{"name":"CapsoVision, Inc.","relationship":"former employer of new CFO"},{"name":"Abzena Biologics","relationship":"former employer of new CFO"},{"name":"Revance Therapeutics","relationship":"former employer of new CFO"},{"name":"Genentech/Roche","relationship":"former employer of new CFO"},{"name":"Caterpillar","relationship":"former employer of new CFO"},{"name":"Abbott Laboratories","relationship":"former employer of new CFO"}],"dollarAmounts":[{"amount":"$6 billion","context":"annual revenue of Caterpillar's Japan division previously overseen by Kevin Lundquist"}]},"materialImpact":{"score":3,"reasoning":"Appointment of a seasoned CFO with specific experience in commercial launches and capital markets is a positive signal as the company transitions to commercialization, though not a market-moving binary event."},"tickerRelevance":{"others":[],"primary":"OTLK"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"executive_hire","sectorWeight":"biotech"}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Outlook Therapeutics appointed Kevin Lundquist as Chief Financial Officer, effective September 1, 2026, bringing over 20 years of experience in pharmaceutical and medical technology finance to the role as the company prepares for the U.S. commercial launch of LYTENAVA.\n\nOutgoing CFO Lawrence Kenyon will step down on September 1 but will remain as a non-executive employee through the end of the month to ensure a smooth transition.\n\nThe company issued an inducement grant to Mr. Lundquist for an option to purchase 500,000 shares of common stock, vesting over four years.","key_figures":{"customDimensions":{"inducement_grant_shares":500000}},"named_entities":{"people":[{"name":"Kevin Lundquist","role":"Chief Financial Officer"},{"name":"Bob Jahr","role":"Chief Executive Officer"},{"name":"Lawrence Kenyon","role":"Outgoing Chief Financial Officer"}],"products":["LYTENAVA™"],"companies":[{"name":"Outlook Therapeutics, Inc.","ticker":"OTLK"},{"name":"CapsoVision, Inc.","relationship":"former employer of new CFO"},{"name":"Abzena Biologics","relationship":"former employer of new CFO"},{"name":"Revance Therapeutics","relationship":"former employer of new CFO"},{"name":"Genentech/Roche","relationship":"former employer of new CFO"},{"name":"Caterpillar","relationship":"former employer of new CFO"},{"name":"Abbott Laboratories","relationship":"former employer of new CFO"}],"dollarAmounts":[{"amount":"$6 billion","context":"annual revenue of Caterpillar's Japan division previously overseen by Kevin Lundquist"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-27T20:21:35.632Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"executive_hire","sectorWeight":"biotech"}},"durationMs":89825,"modelName":"glm-4.7"}}